Targeting conserved N-glycosylation blocks SARS-CoV-2 variant infection in vitro

• Published in: EBioMedicine Vol. 74; p. 103712
• Main Authors: Huang, Hsiang-Chi, Lai, Yun-Ju, Liao, Chun-Che, Yang, Wang-Feng, Huang, Ke-Bin, Lee, I-Jung, Chou, Wen-Cheng, Wang, Shih-Han, Wang, Ling-Hui, Hsu, Jung-Mao, Sun, Cheng-Pu, Kuo, Chun-Tse, Wang, Jyun, Hsiao, Tzu-Chun, Yang, Po-Jiun, Lee, Te-An, Huang, Wilson, Li, Fu-An, Shen, Chen-Yang, Lin, Yi-Ling, Tao, Mi-Hua, Li, Chia-Wei
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01-12-2021; Elsevier
• Subjects: A549 Cells; ADC; Animals; Antibodies, Neutralizing - immunology; Antibodies, Viral - immunology; Benzamides - pharmacology; Cell Line; COVID-19 - drug therapy; Deglycosylation; Glycosylation - drug effects; HEK293 Cells; Hexosyltransferases - antagonists & inhibitors; Hexosyltransferases - metabolism; Humans; Membrane Proteins - antagonists & inhibitors; Membrane Proteins - metabolism; Mice; Mice, Inbred C57BL; NGI-1; Research paper; SARS-CoV-2 - growth & development; SARS-CoV-2 variant; Spike Glycoprotein, Coronavirus - metabolism; STT3A; Sulfonamides - pharmacology; Virus Internalization - drug effects; ADC; STT3A/B; Deglycosylation; ACE2; OST; SARS-CoV-2; SARS-CoV-2 variant; GWAS; RBD; STT3A; NGI-1; eQTL
• ISSN: 2352-3964; 2352-3964
• DOI: 10.1016/j.ebiom.2021.103712

Despite clinical success with anti-spike vaccines, the effectiveness of neutralizing antibodies and vaccines has been compromised by rapidly spreading SARS-CoV-2 variants. Viruses can hijack the glycosylation machinery of host cells to shield themselves from the host's immune response and attenuate antibody efficiency. However, it remains unclear if targeting glycosylation on viral spike protein can impair infectivity of SARS-CoV-2 and its variants.
We adopted flow cytometry, ELISA, and BioLayer interferometry approaches to assess binding of glycosylated or deglycosylated spike with ACE2. Viral entry was determined by luciferase, immunoblotting, and immunofluorescence assays. Genome-wide association study (GWAS) revealed a significant relationship between STT3A and COVID-19 severity. NF-κB/STT3A-regulated N-glycosylation was investigated by gene knockdown, chromatin immunoprecipitation, and promoter assay. We developed an antibody-drug conjugate (ADC) that couples non-neutralization anti-spike antibody with NGI-1 (4G10-ADC) to specifically target SARS-CoV-2-infected cells.
The receptor binding domain and three distinct SARS-CoV-2 surface N-glycosylation sites among 57,311 spike proteins retrieved from the NCBI-Virus-database are highly evolutionarily conserved (99.67%) and are involved in ACE2 interaction. STT3A is a key glycosyltransferase catalyzing spike glycosylation and is positively correlated with COVID-19 severity. We found that inhibiting STT3A using N-linked glycosylation inhibitor-1 (NGI-1) impaired SARS-CoV-2 infectivity and that of its variants [Alpha (B.1.1.7) and Beta (B.1.351)]. Most importantly, 4G10-ADC enters SARS-CoV-2-infected cells and NGI-1 is subsequently released to deglycosylate spike protein, thereby reinforcing the neutralizing abilities of antibodies, vaccines, or convalescent sera and reducing SARS-CoV-2 variant infectivity.
Our results indicate that targeting evolutionarily-conserved STT3A-mediated glycosylation via an ADC can exert profound impacts on SARS-CoV-2 variant infectivity. Thus, we have identified a novel deglycosylation method suitable for eradicating SARS-CoV-2 variant infection in vitro.
A full list of funding bodies that contributed to this study can be found in the Acknowledgements section
4G10-ADC targets and enters SARS-CoV-2 infected cells. NGI-1 is released from the ADC to block spike glycosylation. Virions with non-glycosylated spike display a higher antibody binding affinity and low infectivity. [Display omitted]